STRS Ohio’s NovoCure NVCR Stock Holding History

STRS Ohio’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$971K	Buy	64,100 +4,700	+8%	+$71.1K	﹤0.01%	755
2026 Q1	$647K	Buy	59,400 +1,300	+2%	+$16.2K	﹤0.01%	892
2025 Q4	$751K	Sell	58,100 -1,100	-2%	-$14.1K	﹤0.01%	815
2025 Q3	$765K	Buy	59,200 +12,800	+28%	+$171K	﹤0.01%	792
2025 Q2	$826K	Buy	46,400 +3,800	+9%	+$66.2K	﹤0.01%	993
2025 Q1	$759K	Buy	42,600 +6,800	+19%	+$154K	﹤0.01%	976
2024 Q4	$1.07M	Sell	35,800 -8,700	-20%	-$184K	﹤0.01%	831
2024 Q3	$696K	Hold	44,500	–	–	﹤0.01%	1057
2024 Q2	$762K	Buy	+44,500	New	+$783K	﹤0.01%	983
2023 Q3	–	Sell	-14,991	Closed	-$622K	–	2016
2023 Q2	$622K	Buy	14,991 +5,524	+58%	+$343K	﹤0.01%	1152
2023 Q1	$569K	Sell	9,467 -1,584	-14%	-$127K	﹤0.01%	1227
2022 Q4	$810K	Buy	+11,051	New	+$832K	﹤0.01%	1030
2021 Q3	–	Sell	-5,743	Closed	-$1.27M	–	2296
2021 Q2	$1.27M	Sell	5,743 -1,835	-24%	-$357K	﹤0.01%	1015
2021 Q1	$1M	Buy	7,578 +1,834	+32%	+$290K	﹤0.01%	1170
2020 Q4	$993K	Buy	+5,744	New	+$786K	﹤0.01%	1064
2020 Q2	–	Sell	-28,000	Closed	-$1.89M	–	2222
2020 Q1	$1.89M	Sell	28,000 -1,000	-3%	-$79K	0.01%	579
2019 Q4	$2.44M	Buy	29,000 +1,500	+5%	+$121K	0.01%	630
2019 Q3	$2.06M	Buy	27,500 +3,500	+15%	+$280K	0.01%	643
2019 Q2	$1.52M	Buy	24,000 +15,100	+170%	+$765K	0.01%	704
2019 Q1	$428K	Buy	8,900 +2,800	+46%	+$135K	﹤0.01%	1375
2018 Q4	$204K	Sell	6,100 -1,700	-22%	-$62.2K	﹤0.01%	1631
2018 Q3	$408K	Buy	+7,800	New	+$310K	﹤0.01%	1475
2016 Q3	–	Sell	-1,400	Closed	-$12.8K	–	1940
2016 Q2	$16K	Hold	1,400	–	–	﹤0.01%	1872
2016 Q1	$20K	Sell	1,400 -1,400	-50%	-$20.1K	﹤0.01%	1822
2015 Q4	$62K	Buy	+2,800	New	+$66.9K	﹤0.01%	1759

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

STRS Ohio's NVCR Position: Q2 2026 in Review

STRS Ohio increased its NovoCure (NVCR) stake by 7.9% in Q2 2026, buying an estimated $71.1K and bringing the position to 64,100 shares worth $971K. The position accounts for ﹤0.01% of the portfolio, ranked #755.

STRS Ohio first reported a position in NVCR in Q4 2015 and has held it in 25 quarters since. The position peaked at $2.44M in Q4 2019. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

STRS Ohio held 64,100 shares of NovoCure worth $971K as of Q2 2026.
STRS Ohio bought 4,700 NovoCure shares in Q2 2026, an estimated $71.1K.
NovoCure made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #755 holding.
STRS Ohio first reported a position in NovoCure in Q4 2015 and has held it in 25 quarters since.
STRS Ohio's NovoCure position peaked at $2.44M in Q4 2019.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.